Independent peptide analysis, vendor accountability, and evidence-based guidance. No vendor sponsorship. No pay-for-play reviews.https://peptideexaminer.com/en-ushttps://peptideexaminer.com/articles/fda-peptide-reclassification-2026/https://peptideexaminer.com/articles/fda-peptide-reclassification-2026/Independent analysis of the FDA peptide reclassification. RFK announced it Feb 27. As of late March, no formal FDA action. What you need to know.Sat, 28 Mar 2026 00:00:00 GMTfdareclassificationrfk-jrcategory-2category-1compoundingregulationbpc-157peptides-legalhttps://peptideexaminer.com/articles/peptide-news-late-march-2026/https://peptideexaminer.com/articles/peptide-news-late-march-2026/FDA still hasn't published peptide reclassification 29 days after RFK announcement. NPR coverage drives new audience. SAFE Drugs Act bill text on Congress.gov.Sat, 28 Mar 2026 00:00:00 GMTregulationFDAenforcementreclassificationSAFE Drugs ActNPRgrey-marketnewshttps://peptideexaminer.com/articles/where-to-buy-bpc-157/https://peptideexaminer.com/articles/where-to-buy-bpc-157/Independent guide to buying BPC-157 in 2026. Grey-market vendors rated, compounding pharmacy options, and what the FDA reclassification means for access.Sat, 28 Mar 2026 00:00:00 GMTbpc-157buying-guidevendorsgrey-marketcompoundingwhere-to-buyhttps://peptideexaminer.com/articles/where-to-buy-peptides-2026/https://peptideexaminer.com/articles/where-to-buy-peptides-2026/Complete guide to buying peptides in 2026. Grey-market vendors rated, compounding pharmacy pathways, telehealth options, and what the reclassification means.Sat, 28 Mar 2026 00:00:00 GMTbuying-guidevendorsgrey-marketcompoundingtelehealthwhere-to-buypeptideshttps://peptideexaminer.com/articles/where-to-buy-semaglutide/https://peptideexaminer.com/articles/where-to-buy-semaglutide/Guide to legal semaglutide access in 2026. FDA-approved Ozempic, Wegovy, Oral Wegovy ($149/mo), and why grey-market semaglutide should be avoided.Sat, 28 Mar 2026 00:00:00 GMTsemaglutidebuying-guideozempicwegovyglp-1weight-losswhere-to-buyhttps://peptideexaminer.com/articles/peptide-news-mid-march-2026/https://peptideexaminer.com/articles/peptide-news-mid-march-2026/Peptide Sciences shuts down. The FDA still hasn't published reclassification. The SAFE Drugs Act threatens the RUO model.Sat, 14 Mar 2026 00:00:00 GMTregulationFDAenforcementPeptide Sciencesgrey-marketSAFE Drugs ActFinnrickhttps://peptideexaminer.com/articles/why-did-peptide-sciences-close-down/https://peptideexaminer.com/articles/why-did-peptide-sciences-close-down/Analysis of why Peptide Sciences shut down on March 6, 2026. FDA enforcement, Big Pharma litigation, and quality failures ended the grey-market era.Sat, 14 Mar 2026 00:00:00 GMTpeptide-sciencesshutdownenforcementfdagrey-marketvendorfinnrickhttps://peptideexaminer.com/articles/cjc-1295-ipamorelin-combination/https://peptideexaminer.com/articles/cjc-1295-ipamorelin-combination/Deep analysis of CJC-1295 and ipamorelin — the most used GH secretagogue stack. Mechanism, evidence gaps, and what community protocols actually rest on.Mon, 02 Mar 2026 00:00:00 GMTcjc-1295ipamorelingrowth-hormonesecretagoguecombination-therapymod-grf-1-29ghrhghrpstackhttps://peptideexaminer.com/articles/march-2026-peptide-roundup/https://peptideexaminer.com/articles/march-2026-peptide-roundup/RFK Jr. announces reclassification of 14 Category 2 peptides on Joe Rogan. Hims & Hers confirms peptide line. HIMS stock surges.Mon, 02 Mar 2026 00:00:00 GMTnewsfdaregulationrfk-jrreclassificationhims-herscategory-2compoundingjoe-roganmarkethttps://peptideexaminer.com/articles/february-2026-peptide-roundup/https://peptideexaminer.com/articles/february-2026-peptide-roundup/Monthly roundup: MIT Technology Review's peptide feature, RFK Jr.'s FDA influence, Chinese import crackdown, and regulatory uncertainty.Wed, 25 Feb 2026 00:00:00 GMTnewsfdaregulationmarketmit-technology-reviewrkf-jrchina-importsenforcementhttps://peptideexaminer.com/articles/sermorelin-testosterone-combination/https://peptideexaminer.com/articles/sermorelin-testosterone-combination/Evidence-based analysis of sermorelin + testosterone therapy. What studies show about GH-testosterone synergy and body composition.Wed, 25 Feb 2026 00:00:00 GMTsermorelintestosteroneTRTgrowth-hormonebody-compositionhypogonadismcombination-therapyhttps://peptideexaminer.com/articles/fda-peptide-crackdown-timeline/https://peptideexaminer.com/articles/fda-peptide-crackdown-timeline/Timeline of FDA enforcement actions against peptide vendors from 2023-2026: warning letters, criminal cases, and regulatory changes.Fri, 20 Feb 2026 00:00:00 GMTfdaregulationenforcementcompoundingwarning-letterslegalhttps://peptideexaminer.com/articles/fda-peptide-enforcement-2025-guide/https://peptideexaminer.com/articles/fda-peptide-enforcement-2025-guide/Complete timeline of FDA and ITC enforcement actions against peptide vendors from 2024-2026. Warning letters, exclusion orders, and the BPC-157 ban.Fri, 20 Feb 2026 00:00:00 GMTfdaregulationenforcementcompoundingwarning-lettersitclegalhttps://peptideexaminer.com/articles/getting-started-with-peptides/https://peptideexaminer.com/articles/getting-started-with-peptides/New to peptides? Our beginner's guide covers what peptides are, how to evaluate vendors, safety considerations, and what to know first.Fri, 20 Feb 2026 00:00:00 GMTbeginnerguidesafetyvendor-selectionpeptide-basicshttps://peptideexaminer.com/articles/grey-market-quality-crisis/https://peptideexaminer.com/articles/grey-market-quality-crisis/Analysis of independent testing data revealing alarming quality failures in grey-market peptides. What Finnrick, Janoshik, and other labs have found.Fri, 20 Feb 2026 00:00:00 GMTqualitytestingcoapuritycontaminationgrey-marketsafetyhttps://peptideexaminer.com/articles/infiniwell-review-snac-claims/https://peptideexaminer.com/articles/infiniwell-review-snac-claims/Independent deep dive into Infiniwell's SNAC-enhanced BPC-157 products. We examine the technology claims, the missing studies, and what consumers should know.Fri, 20 Feb 2026 00:00:00 GMTinfiniwellsnacbpc-157vendor-reviewbioavailabilityoral-peptideshttps://peptideexaminer.com/articles/pda-vs-bpc-157-same-peptide/https://peptideexaminer.com/articles/pda-vs-bpc-157-same-peptide/Analysis of Pentadeca Arginate (PDA) claims: the patent, the chemistry, and the missing evidence behind '99% bioavailability' marketing.Fri, 20 Feb 2026 00:00:00 GMTbpc-157pdabioavailabilityoral-peptidesvendor-claimshttps://peptideexaminer.com/articles/semaglutide-compounding-crisis/https://peptideexaminer.com/articles/semaglutide-compounding-crisis/How semaglutide went from pharmaceutical breakthrough to public health crisis. The compounding controversy, counterfeit risks, and what consumers need to know.Fri, 20 Feb 2026 00:00:00 GMTsemaglutideglp-1ozempicwegovycompoundingfdacounterfeitsafetyhttps://peptideexaminer.com/articles/oral-peptides-bioavailability-guide/https://peptideexaminer.com/articles/oral-peptides-bioavailability-guide/Learn which peptides have genuine oral bioavailability and which don't. Science-based guide to absorption technologies like SNAC and liposomes.Fri, 20 Feb 2026 00:00:00 GMToral-peptidesbioavailabilityabsorptionSNACBPC-157guidehttps://peptideexaminer.com/articles/tb500-vs-thymosin-beta4-fragment-problem/https://peptideexaminer.com/articles/tb500-vs-thymosin-beta4-fragment-problem/Critical analysis of TB-500 vs. Thymosin Beta-4. The research uses one molecule; the market sells another. We examine what the evidence actually supports.Fri, 20 Feb 2026 00:00:00 GMTtb-500thymosin-beta-4regenerativeevidence-reviewgrey-markethttps://peptideexaminer.com/articles/oral-bpc-157-bioavailability/https://peptideexaminer.com/articles/oral-bpc-157-bioavailability/An evidence-based analysis of oral BPC-157 bioavailability claims. We examine what the research actually shows versus what vendors tell you.Wed, 18 Feb 2026 00:00:00 GMTbpc-157bioavailabilityoral-peptidesevidence-reviewhttps://peptideexaminer.com/articles/fda-warning-letters-september-2025/https://peptideexaminer.com/articles/fda-warning-letters-september-2025/Analysis of the FDA's September 2025 enforcement wave: 50+ warning letters to peptide and GLP-1 compounders in a single month.Sun, 08 Feb 2026 00:00:00 GMTfdaregulationwarning-letterscompoundingsemaglutideenforcementhttps://peptideexaminer.com/articles/how-to-read-peptide-coa/https://peptideexaminer.com/articles/how-to-read-peptide-coa/Learn to evaluate peptide COAs: what each test means, red flags for fake documentation, and which labs are considered credible.Thu, 05 Feb 2026 00:00:00 GMTcoaquality-testingbuyer-guidehplcmass-specendotoxin